Malaysia Cardiovascular Drugs Market Analysis Report 2022 to 2030

Malaysia Cardiovascular Drugs Market Analysis

$ 3999

Malaysia Cardiovascular Drug Market is at around $0.22 Bn in 2022 and is projected to reach $0.30 Bn in 2030, exhibiting a CAGR of 4% during the forecast period. The market is driven by factors such as the aging population, increasing incidence of cardiovascular diseases, and enhanced screening and diagnostics. The market is dominated by key players like Pharmaniaga Berhad, Duopharma Biotech Bhd, B Braun Medical Industries (M) Sdn Bhd, Eschol Pharmaceuticals Sdn Bhd, CCM Pharmaceuticals (SGP), Pfizer Inc., Astra Zeneca, Sanofi, Zydus, and Lupin.

ID: IN10MYPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Aneri Parekh

Buy Now

Malaysia Cardiovascular Drug Market Executive Summary

Malaysia Cardiovascular Drug Market is at around $0.22 Bn in 2022 and is projected to reach $0.30 Bn in 2030, exhibiting a CAGR of 4% during the forecast period.

Ailments affecting both the heart and blood arteries are referred to as cardiovascular illnesses. Deep vein thrombosis, pulmonary embolism, peripheral artery disease, congenital heart disease, rheumatic heart disease, and coronary heart disease are a few of these. The three main drug types used to treat heart-related conditions are ACE inhibitors (like ramipril), antiarrhythmics (like amiodarone), and angiotensin-II antagonists (like losartan).

Demand for cardiovascular drugs is driven by risk factors like obesity, diabetes, and physical inactivity that are brought on by increased urbanization and sedentary lifestyles. Additional, ongoing research and development initiatives provide novel, more potent, and maybe safer cardiovascular medications. The market is growing as a result of these innovations drawing in patients and healthcare professionals.

Over the previous two decades, pharmaceutical revenues rose rapidly, reaching $138.33 Bn globally in 2022. With the introduction of new technologies and more economical and effective manufacturing techniques, the pharmaceutical industry has undergone a significant transformation. Furthermore, the growing amount of capital flowing into this sector has helped to propel the market's expansion.

The primary focus of Pharmaniaga is the development and production of superior generic versions of well-known cardiovascular medications. This approach increases the affordability and accessibility of their treatments for a larger group of patients.

Malaysia cardiovascular drug market

Market Dynamics

Market Growth Drivers:

Aging Population: Malaysia's population is aging quickly, with 15% of seniors over 65 predicted to be in the country by 2030. This means that those who live there are more likely to get cardiac problems, hypertension, and coronary artery disease, hence, growing the market for cardiovascular drugs.

Cardiovascular Disease Prevalence: In Malaysia, ischemic heart disorders were the top cause of death in 2022, accounting for 20,322 fatalities or 16.1% of all medically certified deaths. Ischemic heart problems have been the primary cause of death for the past 20 years.

Enhanced Screening and Diagnosis: Increasing awareness of cardiovascular illnesses and the development of diagnostic techniques drive the growth of the market.

Market Restraints:

Healthcare Spending Pressure: To control healthcare costs, the government and healthcare providers may impose limitations on the reimbursement of expensive pharmaceuticals.

Income Inequality: Inequality in income can lead to unequal access to cutting-edge cardiovascular drugs and a possible exacerbation of health disparities among the population.

Notable Recent Updates

July 2023, Pharmaniaga Bhd and the Ministry of Health (MOH) have signed a concession agreement (CA) for Pharmaniaga Bhd to handle the purchase, storage, supply, and delivery of medicinal supplies to MOH-run facilities and offices

Healthcare Policies and Regulatory Landscape

Drug Control Authority (DCA) is the executive agency responsible for overseeing the registration process for novel pharmaceuticals and biologics in Malaysia, as per the Control of Pharmaceuticals and Cosmetics Regulations 1984. Applying online via the QUEST3 system is required. Users can do safe online actions for product registration applications using QUEST online membership registration. To comply with international requirements for Good Clinical Practice and Good Manufacturing Practice, such as those set forth by the International Council on Harmonization (ICH), DCA requires high-quality data and stringent protocol adherence, which can add complexity and potentially extend timescales. Due to the wide range of ethnic groups in Malaysia, thorough evaluations of medication safety and efficacy across various populations are necessary. This may call for further clinical trials or data analysis, which would raise prices and complicate matters.

Competitive Landscape

Key Players:

Pharmaniaga Berhad
Duopharma Biotech Bhd
B Braun Medical Industries (M) Sdn Bhd
Eschol Pharmaceuticals Sdn bhd
CCM Pharmaceuticals (SGP)
Pfizer Inc.
Astra Zeneca
Sanofi
Zydus
Lupin

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Others

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.